Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 EUR | -6.67% | +0.80% | +4.56% |
04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.56% | 38.95M | |
-11.79% | 292M | |
-.--% | 62.2M | |
-20.59% | 59.83M |
- Stock Market
- Equities
- ADMIN Stock
- News Administer Oyj
- Defence Therapeutics Secures FDA Consent for Phase I Clinical Trial Targeting Solid Cancer Tumors With AccuTOX